Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gustavo Eduardo Velasquez, M.D.


This page shows the publications co-authored by Gustavo Velasquez and Carole Mitnick.
Connection Strength

  1. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168.
    View in: PubMed
    Score: 0.813
  2. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
    View in: PubMed
    Score: 0.777
  3. Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. Int J Tuberc Lung Dis. 2018 05 01; 22(5):473-474.
    View in: PubMed
    Score: 0.759
  4. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
    View in: PubMed
    Score: 0.240
  5. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017 08 01; 21(8):894-901.
    View in: PubMed
    Score: 0.180
  6. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 11; 60(11):6766-6773.
    View in: PubMed
    Score: 0.171
  7. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15.
    View in: PubMed
    Score: 0.143
  8. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. Clin Infect Dis. 2022 01 29; 74(2):343-346.
    View in: PubMed
    Score: 0.061
  9. The fourth national anti-tuberculosis drug resistance survey in Peru. Int J Tuberc Lung Dis. 2020 02 01; 24(2):207-213.
    View in: PubMed
    Score: 0.054
  10. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.